
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer
New data from an ongoing phase 2a trial (NCT05585320) suggest that atebimetinib (IMM-1-104), an oral, once-daily novel MEK inhibitor, in combination with modified gemcitabine/nab-paclitaxel (mGnP), may offer significant survival benefits in the first …